



Order ID B26367  
 Provider Sample Provider MD

**Specimen**  
 Collected 09/23/2024  
 Received 09/24/2024  
**Test Order**  
 Created 09/24/2024  
 Reported 09/27/2024

**Patient**  
**Sample, Susan**  
 Gender - DOB Female - 01/01/2001  
 MRN MRN12345

## AVISE SLE Prognostic Test Report

Analyte	Value	Interpretation	Reference Range
+ Anti-C1q IgG	48.6 Units	POSITIVE	<20 - Negative   ≥20 - Positive
Anti-Ribosomal P IgG	1.3 U/mL	Negative	<7 - Negative   7-10 - Equivocal   >10 - Positive
Anti-Phosphatidylserine/Prothrombin IgM	18.44 Units	Negative	≤30 - Negative   >30 - Positive
Anti-Phosphatidylserine/Prothrombin IgG	17.28 Units	Negative	≤30 - Negative   >30 - Positive
Anti-Cardiolipin IgM	2.5 MPL	Negative	<10 - Negative   10-40 - Weak Positive   >40 - Positive
+ Anti-Cardiolipin IgG	98.7 GPL	POSITIVE	<10 - Negative   10-40 - Weak Positive   >40 - Positive
Anti-Cardiolipin IgA	4.6 APL	Negative	<14 - Negative   14-20 - Equivocal   >20 - Positive
+ Anti-β2 Glycoprotein 1 IgM	20.3 U/mL	POSITIVE	<7 - Negative   7-10 - Equivocal   >10 - Positive
Anti-β2 Glycoprotein 1 IgG	1.9 U/mL	Negative	<7 - Negative   7-10 - Equivocal   >10 - Positive
Anti-β2 Glycoprotein 1 IgA	6.7 U/mL	Negative	<7 - Negative   7-10 - Equivocal   >10 - Positive

### Test Method Description

Results were obtained by Enzyme Linked Immunosorbent Assay (ELISA) for determination of Anti-C1q IgG and Anti-Phosphatidylserine/Prothrombin (PS/PT) IgM and IgG antibodies. Results were obtained by Enzyme Linked Fluorescent Immunoassay (ELFA) for determination of cardiolipin IgM, IgG, IgA antibodies, β2-glycoprotein 1 IgM, IgG, IgA antibodies, and Ribosomal-P antibodies.

### References

- Akhter E, et al. J Rheumatol. 2013 Mar;40(3):282-286. doi: 10.3899/jrheum.120084.
- Sciascia S, et al. J Thromb Haemost. 2012 Dec;10(12):2512-8. doi: 10.1111/jth.12014.
- Yin Y, et al. Lupus. 2012 Sep;21(10):1088-97. doi: 10.1177/0961203312451202.
- Akhter E, et al. 2011 Oct;20(12):1267-74. doi: 10.1177/0961203311411597.
- Hanly J, et al. Ann Rheum Dis. 2011 Oct;70(10):1726-32. doi: 10.1136/ard.2010.148502.
- Shen Y, et al. Lupus. 2008 Nov;17(11):996-1003. doi: 10.1177/0961203308093460.
- Miyakis S, et al. J Thromb Haemost. 2006 Feb;4(2):295-306. doi: 10.1111/j.1538-7836.2006.01753.x.
- References INOVA Markers references and results (INOVA product inserts).



1261 Liberty Way, Vista CA 92081  
 CLIA# 05D1075048  
 CAP# 7201051 | NYSDOH PFI# 8369

Laboratory Director:  
 Prashanti Reddy, M.D.

Provider Relations: 888.452.1522

Exagen, AVISE and the Exagen and AVISE logos are registered trademarks of Exagen Inc. ©2024 All Rights Reserved

This test was developed and its performance characteristics determined by Exagen. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform high complexity clinical laboratory testing.